SciELO - Scientific Electronic Library Online

 
vol.66 número1Diseño e implantación de un programa electrónico de farmacovigilancia con captura en línea en el Hospital Infantil de México Federico GómezBurkholderia cepacia y enfermedad granulomatosa crónica: Informe de un caso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Boletín médico del Hospital Infantil de México

versión impresa ISSN 1665-1146

Resumen

OLAYA-VARGAS, Alberto et al. Evaluation of treatment with VAMP plus involved-field radiation in Mexican pediatric patients with early-stage Hodgkin lymphoma. Bol. Med. Hosp. Infant. Mex. [online]. 2009, vol.66, n.1, pp.60-67. ISSN 1665-1146.

Introduction. Purpose: To evaluate outcome and assess toxicity of patients with early-stage Hodgkin lymphoma treated with VAMP and low-dose involved-field radiation. Methods. Patients with clinical favorable stages Hodgkin lymphoma were treated with 4 cycles of VAMP (vinblastine 6 mg/m2sc, doxorrubicyn 25 mg/m2sc, methotrexate 20 mg/ m2sc, and prednisone 40 mg/m2sc) administrated on day 1 and day 15. And 21.6 Gy involvedfied radiation. The over-all survival was estimated using Kaplan-Meier and Cox methods. Results. 17 patients were included, the median age was 7 years. Two patients present progressive disease at 4 and 16 months respectively. The overall survival were 94.12% with follow-up of 66 months (IC 95%), the event-free survival were 88.24% with follow up of 63 months (IC 95%). Conclusions. The combined modality therapy with chemotherapy and involved-field radiation (21.6 Gy) shows a better overall survival. The radiation toxicity was elevated, for that reason we must try to reduce the dose of radiotherapy at 15 Gy in patients with complete response to treatment.

Palabras llave : Hodgkin lymphoma; VAMP; involved-field radiation.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons